NIDA Clinical Trials Network: Big South/West Node

NIDA 临床试验网络：大南/西节点

• 批准号: 10581485
• 负责人: Jennifer Sharpe Potter
• 金额: $ 888.89万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10581485
• 关键词: AIDS prevention; Academy; Acceleration; Address; African American; American; American Indians; Ancillary Study; Area; Arkansas; Buprenorphine; Bupropion; California; Caring; Cause of Death; Clinical; Clinical Treatment; Clinical Trials Network; Collaborations; Communities; Databases; Development; Doctor of Philosophy; Dose; Drug abuse; Drug usage; Electronic Health Record; Ethnic Population; Evidence based practice; Family Physicians; Foundations; Funding; Genetic Complementation Test; Geographic Locations; Geography; Goals; HIV; HIV Seropositivity; HIV/HCV; Health; Health Sciences; Healthcare Systems; Hepatitis C virus; Hispanic; Immigrant; Informatics; Infrastructure; International; Lead; Leadership; Length of Stay; Los Angeles; Louisiana; Measurement; Medical center; Mentors; Methamphetamine; Methamphetamine use disorder; Mission; Modeling; Multi-Institutional Clinical Trial; Naltrexone; Names; National Institute of Drug Abuse; Oklahoma; Opioid; Patient Discharge; Peer Review; Persons; Pharmacotherapy; Policy Maker; Population; Primary Care; Productivity; Public Health; Publications; Publishing; Recovery; Research; Research Design; Research Personnel; Resources; Risk; Rural; Scholars Program; Science; Scientist; Senior Scientist; Site; Solid; Stimulant; Substance Use Disorder; Texas; Training; Transcranial magnetic stimulation; Translational Research; Underinsured; Universities; Workforce Development; addiction; clinical care; cohort; comorbidity; design; dissemination science; experience; health care settings; hospital readmission; implementation science; implementation study; improved; indexing; innovation; medically underserved population; metropolitan; multi-site trial; next generation; novel; opioid epidemic; opioid use disorder; patient population; prevention practice; programs; racial diversity; racial population; readmission risk; response; risk prediction; rural area; rural setting; screening; stimulant use; stimulant use disorder; substance misuse; substance use; therapy development; underserved area; urban setting

ABSTRACT The Big South/West Node of the NIDA Clinical Trials Network (CTN) represents an expansion of the Texas Node that has been a part of the CTN since 2005. With this expansion, the node will now be guided by the shared leadership of Madhukar H. Trivedi, MD of University of Texas Southwestern Medical Center (UTSW) Steven Shoptaw, PhD of UCLA, and Jennifer S. Potter, PhD, MPH, of UT Health Science Center at San Antonio (UTHSCSA). This fourth competing renewal application builds on our successful track record of leading CTN trials, being good network partners by providing excellent sites for multi-site studies, high productivity in publishing, and training the next generation of scientists. During the 2015-2020 funding cycle, our team developed and led: the largest pharmacotherapy trial for the treatment of methamphetamine use disorder to date (extended-release naltrexone plus high-dose bupropion; CTN0068 ADAPT-2), an in-depth study of the causes of death in a cohort of people living with HIV/HCV and substance use disorder (CTN0064A1), and an implementation study to develop and deploy universal screening for opioid use disorder and measurement based care using buprenorphine (CTN0090 MBC4OUD). Finally, a study testing transcranial magnetic stimulation (TMS) as a treatment for stimulant use disorder has been approved for development, in collaboration with the Southern Consortium Node (CTN0108). For this renewal application, we capitalize on the experience of the Multiple PIs, who collectively have expertise in the treatment of stimulants, the treatment of and public health response to the opioid crisis, and the treatment and care of HIV. Additional investigators bring content expertise spanning addiction science and clinical care, translational science, dissemination and implementation science, informatics, and trial implementation. The expanded Big South/West Node is named to denote the importance of including geographic regions in the South that have historically not been represented within the CTN (i.e., Arkansas, Oklahoma, Louisiana). This geographical expansion provides greater access to diverse patient populations (e.g., diverse racial and ethnic groups; underinsured; underserved; native [American Indian] and immigrant groups) within diverse settings (e.g., rural, urban). Our existing partnerships with primary care networks, large health care systems, and use of electronic health records (EHR) to positively impact substance use, has been further broadened to include multiple statewide networks and resources in new partner states. Our research agenda includes a focus on the fourth wave of the opioid epidemic, building upon the expertise of our investigators in treating stimulant and opioid use disorders, and the changing needs of the regions we serve. Our team has experience with innovative study designs that target all areas of the translational science continuum, and equip our Node to successfully and significantly improve the care of persons who misuse substances.

摘要 NIDA临床试验网络（CTN）的大南/西节点代表了德克萨斯州的扩展 自2005年以来一直是CTN的一部分的节点。通过这种扩展，节点现在将由 Madhukar H的共同领导。Trivedi博士，德克萨斯大学西南医学中心（UTSW） 加州大学洛杉矶分校的史蒂芬·肖普托博士和詹妮弗·S·波特，博士，公共卫生硕士，UT健康科学中心在旧金山 Antonio（UTHSCSA）.这第四个竞争性续期申请建立在我们成功的记录， 领先的CTN试验，通过为多中心研究提供优秀的研究中心，成为良好的网络合作伙伴， 提高出版生产力，培养下一代科学家。在2015-2020年供资周期， 我们的团队开发并领导了：治疗甲基苯丙胺使用的最大药物治疗试验 迄今为止的疾病（缓释纳洛酮加高剂量安非他酮; CTN 0068 ADAPT-2），一个深入的 HIV/HCV感染者和物质使用障碍患者队列死亡原因研究 （CTN 0064 A1）和一项实施研究，以开发和部署阿片类药物使用障碍的普遍筛查 以及使用丁丙诺啡（CTN 0090 MBC 4 OUD）的基于测量的护理。最后，一项研究测试了经颅 磁刺激（TMS）作为兴奋剂使用障碍的治疗方法已被批准开发， 与南方联盟节点（CTN 0108）合作。对于此更新应用程序，我们利用 多个PI的经验，他们共同拥有治疗兴奋剂的专业知识， 以及对阿片类药物危机的公共卫生反应，以及艾滋病毒的治疗和护理。其他调查员 带来内容专业知识，涵盖成瘾科学和临床护理，转化科学，传播和 实施科学、信息学和试验实施。扩展后的Big South/West节点被命名为 以表明包括历史上没有被纳入的南方地理区域的重要性， 在CTN内表示（即，阿肯色州、俄克拉荷马州、路易斯安那州）。这一地理扩张提供了 更容易接触到不同的患者群体（例如，不同种族和民族群体;保险不足; 服务不足;土著[美国印第安人]和移民群体）在不同的环境（例如，农村、城市）。我们 与初级保健网络、大型医疗保健系统的现有伙伴关系，以及电子医疗保健的使用 记录（EHR），以积极影响物质使用，已进一步扩大到包括多个全州 新伙伴国的网络和资源。我们的研究议程包括关注第四次浪潮， 阿片类药物流行病，建立在我们的研究人员在治疗兴奋剂和阿片类药物使用障碍的专业知识， 以及我们所服务地区不断变化的需求。我们的团队拥有创新研究设计的经验， 目标是转化科学连续体的所有领域，并装备我们的节点，以成功和显著 改善对滥用药物者的护理。